Carissa Wong, Author at New Scientist Science news and science articles from New Scientist Tue, 03 Nov 2026 19:24:36 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.8 242057827 Vibrating mattress helps clear Alzheimer’s protein from the brain /article/2597081-vibrating-mattress-helps-clear-alzheimers-protein-from-the-brain/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Tue, 03 Nov 2026 10:00:00 +0000 /article/2597081-auto-draft/ 2597081 Allergic reactions after sex should be listed as an antibiotic risk, experts say /article/2596737-allergic-reactions-after-sex-should-be-listed-as-an-antibiotic-risk-experts-say/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Sat, 31 Oct 2026 16:00:00 +0000 /article/2596737-auto-draft/ 2596737 Personalised cancer vaccine expected to be approved next year /article/2595599-personalised-cancer-vaccine-expected-to-be-approved-next-year/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Fri, 23 Oct 2026 14:42:27 +0000 /article/2595599-auto-draft/
A scanning electron micrograph of a melanoma cell
Science Photo Library/Alamy

A personalised mRNA vaccine for melanoma, the deadliest form of skin cancer, is expected to be approved for use in the US, Europe and the UK next year. The vaccine is designed to stimulate immune responses against genetic mutations that are unique to an individual’s cancer. When used alongside standard treatment in a late-stage trial, it substantially cut the risk of cancer recurrence or death within the next two years.

“I think approval could be quick, and next year sounds reasonable,” says at the Institute of Cancer Research in London, who wasn’t involved in the trial.

“It is a huge deal,” says at the University of Manchester, UK, who also wasn’t involved. Thousands of people in the UK alone could benefit from this, based on the trial’s patient population, she says. “It’s highly likely the US and Europe [including the UK] will approve it next year.” However, producing the vaccine is very expensive, and it may not be deemed cost-effective for use on the UK’s National 91ɫÇéƬ Services (NHS), she says.

In August, drug-maker Moderna announced that the vaccine had positive results in a late-stage trial. More specific findings have now been released.

The trial recruited more than 1100 adults who had surgery to remove high-risk melanomas that were likely to recur or spread to distant sites. In the UK, are diagnosed annually, of which are deemed high risk.

Two-thirds of the participants were randomly assigned to receive a bespoke vaccine on top of standard immunotherapy, called pembrolizumab, which helps the immune system find and destroy cancer. Both were delivered every three weeks for up to a year. The remaining participants received placebo injections plus pembrolizumab.

The vaccine is made by genetically sequencing a small sample of a person’s cancer and comparing that sequence with the DNA in the individual’s healthy blood cells. This enables researchers to pinpoint mutations specific to the cancer.

Based on the same technology used in covid-19 vaccines, the cancer vaccine contains mRNA molecules that encode for proteins with up to 34 of those mutations. “The jab contains a fingerprint of proteins specifically associated with the cancer,” says Lee. “This helps [immune] T-cells recognise the cancer better, and then pembrolizumab prevents those T-cells from becoming exhausted once they’ve started attacking the cancer cells.”

About two years after the start of treatment, 82 per cent of the participants who received the vaccine plus pembrolizumab were alive without their cancer recurring, on average, compared with 70 per cent among those on pembrolizumab alone. “It’s a really exciting result,” says Lee. Side effects were similar between the two groups.

The results combine cancer recurrence and death rates into one figure, but since a treated cancer has to recur for it to cause death, this combined measure should be interpreted mostly as a sign of the vaccine reducing recurrence, says Melcher. The participants haven’t been tracked for long enough to robustly determine whether the vaccine improves survival rates. These results should be available within a few years, says Lee.

But because the vaccine has to be tailored to and manufactured for each individual, it is expected to be very costly, which could affect NHS access. “If it was a cheap drug, I’d definitely say it will get approved [for NHS use], but it’s going to be expensive,” says Lee. In January, a report by suggested it would cost around $200,000 per treatment. Moderna and Merck (also known as MSD), which was also involved in the vaccine’s development, did not respond to a request about its cost.

Further research is needed to better understand who is mostly likely to benefit from the vaccine, says Melcher. Some people may have mutations included in their vaccine that fail to stimulate anti-cancer immunity as predicted, or pembrolizumab could work so well that the vaccine can’t lead to further improvement. “If we can find immune markers in the blood or tumour that predict patient responses, we could use those to determine who to give the jab to,” says Melcher.

, also at the Institute of Cancer Research, says personalised vaccines could also work for other types of cancer, such as those affecting the lungs, bladder and kidneys, which are also routinely treated with immunotherapy. Further research is needed to verify this and explore whether the vaccines could work as standalone treatments.

]]>
2595599
Body temperature may drive the higher risk of autoimmune conditions in women /article/2595579-body-temperature-may-drive-the-higher-risk-of-autoimmune-conditions-in-women/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Fri, 23 Oct 2026 13:50:41 +0000 /article/2595579-auto-draft/ 2595579 Adults may be more creative than children – but less confident about it /article/2595359-adults-may-be-more-creative-than-children-but-less-confident-about-it/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Thu, 22 Oct 2026 12:16:04 +0000 /article/2595359-auto-draft/
The benefits of being creative span generations
Westend61 GmbH / Alamy

Adults are often thought to be less creative than children, as we swap painting for presentations and sandpits for spreadsheets. But in a new study, children actually performed worse on creativity tests than adults – yet made up for it in confidence.

“We found that adults are actually more creative thinkers,” says at the University of Graz in Austria. “But children enjoy creativity more and are much less worried about what others think about their ideas.”

There is a popular belief that children are more creative than adults, he says, which may come from children having more time and opportunities to engage in creative activities. Yet prior research suggests that .

These studies were often based on a single task, like imagining alternative uses for everyday objects, says Benedek. Taking a broader approach, he and his colleagues recruited 92 children (aged between 4 and 7) and 70 adults (aged 25, on average) to carry out three creative tasks.

First, they had to come up with as many alternative uses for a tin can as possible within 3 minutes. Then, they drew freely for 8 minutes, and in the final task, they had 8 minutes to draw an animal that doesn’t exist.

Five people who weren’t involved in the research were then trained to objectively judge creativity based on originality and whether the final result fulfilled the brief of the task.

In the first task, the adults scored 3.9 points, on average, out of 5, while the children scored 2.9 points. One of the adults imagined a tin can could be used as a “Halloween candy box when on (a) diet”, whereas some children imagined it as a rattle.

In the second and third tasks, the adults scored 0.6 and 1.9 points higher, respectively, than the children.

The findings underscore how creativity draws on combining ideas from prior experience, says at King’s College London. For instance, adults are probably aware of more animals than children, so have a greater variety of creatures to draw from when producing a fantasy animal.

After completing the tasks, the participants were asked questions like “How well do you think you performed the task?”, “How much were you worried/anxious to not perform well on the task?” and “How much fun was the task?”.

The researchers found that the children were substantially more confident in what they produced, scoring their performances 4.8 and 4.6 points for the free drawing and animal tasks, respectively, compared with the adults’ 2.8 and 3.3 scoring.

The children also reported lower anxiety compared with the adults. “If the purpose of creativity is to have enjoyment in it, to play and to be unfettered humans, then children are doing better at that,” says Ross.

But the two groups got a similar level of pleasure from the animal-drawing task. Adults may have liked that task’s specific instruction, which may have meant they worried less about being judged for their idea, says Benedek.

Regardless of the quality of the end result, people should try to be more creative for their wellbeing, says Ross. Engaging with the arts has been linked to reduced mental health problems and greater social skills. “Creativity, especially when done with other people, is really beneficial to your mental wellbeing – and you don’t have to score 5 out of 5 on a ranking scale,” she says.

Journal Reference:

PLOS One

]]>
2595359
Probiotic cuts risk of respiratory infections in formula-fed babies /article/2594148-probiotic-cuts-risk-of-respiratory-infections-in-formula-fed-babies/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Thu, 15 Oct 2026 17:00:00 +0000 /article/2594148-auto-draft/ 2594148 Some of our favourite New Scientist Live moments – in photographs /article/2593337-some-of-our-favourite-new-scientist-live-moments-in-photographs/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Wed, 14 Oct 2026 17:00:00 +0000 /article/2593337-some-of-our-favourite-new-scientist-live-moments-in-photographs/ Tim Spector - Mind & Body Stage What not to eat: A conversation with Dr Kandi Ejiofor and Tim Spector OBE New Scientist Live 2026 - Day I
Dr Kandi Ejiofor (right) and epidemiologist Tim Spector unpack the risks in modern diets on the Mind and Body Stage
Alistair Veryard

The hall hummed with joyous curiosity at this year’s New Scientist Live at Excel London, which ran from 10 to 12 October and attracted thousands of visitors of all ages.

With topics including the search for extraterrestrial life, what AI is teaching us about consciousness and the maths behind Pokémon, there was a delightful range to explore. Highlights included physicist Jim Al-Khalili diving into the deepest mysteries of time and psychologist Kimberley Wilson on how to build lifelong brain health. Other packed talks ranged from how we evolved, from anthropologist Alice Roberts, to a myth-busting take on supplements by doctors Chris and Xand van Tulleken.

Alice Roberts - Mind & Body stage Humans: The evolution of a species New Scientist Live 2026 - Day I
Anthropologist and broadcaster Alice Roberts speaks about the evolution of humans
Alistair Veryard
Van Tulleken - Family Stage Make me well: How to outsmart the wellness industry New Scientist Day II 2026
Doctors and presenters Chris (right) and Xand Van Tulleken, plus friend, reveal how to outsmart the wellness industry
Alistair Veryard
New Scientist Day II 2026
A packed audience for doctors Chris and Xand van Tulleken
Alistair Veryard
New Scientist Live 2026 - Day I
Docking with the International Space Station via the British Interplanetary Society’s simulator
Alistair Veryard
New Scientist Live 2026 - Day I
Bumble the brontosaurus greets a visitor
Alistair Veryard

Fans lined up to meet speakers, including naturalist Chris Packham, who shared moving thoughts on why science is crucial to tackling the climate crisis. Younger fans flocked for selfies with mathematician and YouTuber Tom Crawford, who fought a fierce maths battle with maths teacher and TV presenter Bobby Seagull.

New Scientist Live 2026 - Day I
Meeting a robot named Pepper, thanks to the University of Hertfordshire
Alistair Veryard

On the show floor, people could journey through a giant inflatable gut, 3D-print organs and get hands-on with large insects. They also lined up to board a Chinook helicopter, or step into a hospital of the future. Plus, in virtual reality, they could swim through coral reefs and explore the body in 3D.

Walk through a giant gut Global 91ɫÇéƬcare Projects New Scientist Live 2026 - Day I
Intrepid visitors take a trip inside the human digestive system in the Giant Gut Experience
Alistair Veryard
New Scientist Day II 2026
Inside a Royal Air Force Chinook at the show
Alistair Veryard
New Scientist Live 2026 - Day I
Virtual reality, courtesy of the Royal Navy
Alistair Veryard
New Scientist Live 2026 - Day I
A young fan is excited to see presenter Maddie Moate explain how things work
Alistair Veryard
Kimberley Wilson - Mind & Body Stage How to build lifelong brain health New Scientist Live 2026 - Day I
Psychologist and nutrition specialist Kimberley Wilson tells an audience how to build lifelong brain health
Alistair Veryard

Visitors also saw New Scientist staff, including editor Catherine de Lange, predict the biggest scientific breakthroughs in the next 70 years. Plus, podcast editor Rowan Hooper hosted an emergency briefing on the climate crisis, joined by leading climate and biodiversity scientists.

New Scientist Live 2026 - Day I
A Harper Adams University researcher demonstrates seismology in soil
Alistair Veryard
Ann Witheridge - Future Stage Not sure on who the other 2 are ( L and M ) Viewing the Invisible: Artist Ann Witheridge of London Fine Art Studios will live-paint a portrait of Google DeepMind?s Kathryn Tunyasuvunakool, while science-art enthusiast, Rivka Isaacson, professor of molecular biophysics at King?s College London, facilitates a chat about their respective artistic and scientific ways of working, discovering common threads. New Scientist Day II 2026
Artist Ann Witheridge paints a portrait of Kathryn Tunyasuvunakool, a research scientist at Google DeepMind, during a discussion about their ways of working. The talk was hosted by science-art enthusiast Rivka
Isaacson, professor of molecular biophysics at King’s College London
Alistair Veryard
New Scientist Day II 2026
Neuroscientist Hannah Critchlow signs copies of her book The 21st-Century Brain after a talk
Alistair Veryard
New Scientist Day II 2026
The inflatable art installation “Public Anenomes”. Its tentacles are inspired by deep ocean life
Alistair Veryard

The talks were all recorded and will be available to stream online for 12 months. See for details of how to get access.

]]>
2593337
Nobel prize in chemistry awarded for work on mirror molecules /article/2592434-nobel-prize-in-chemistry-awarded-for-work-on-mirror-molecules/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Wed, 07 Oct 2026 09:58:35 +0000 /article/2592434-auto-draft/ Heiner Linke, the chair of the Nobel Committee for Chemistry, explains why Henri Kagan and Kenso Soai are the winners of the 2026 prize during a press conference at the Royal Swedish Academy of Sciences in Stockholm, Sweden
Heiner Linke explains the science behind the 2026 Nobel prize for chemistry
Jonathan Nackstrand/AFP via Getty Images

The 2026 Nobel prize in chemistry has been awarded to Henri Kagan and Kenso Soai for their discovery of how to make molecules form the correct kind of mirror image. This has enabled the molecules to be mass produced with chemical properties that are useful in various applications, such as medicines and agriculture.

Some molecules exist in two forms that are mirror images of each other, which chemists call right- and left-handed. “Like my hands, they are one another’s mirror image, they look alike but they are not identical,” , chair of the Nobel committee for chemistry, said at a press conference. “Such molecules are called chiral from the Greek word for hand.”

For decades, whenever chemists carried out chemical reactions, they produced two forms of mirrored molecules in equal proportions. But they only wanted to make one of the mirror images when producing molecules that would interact with life, like medicines, because only one would have the desired effect.

“Many active drugs in pharmaceutical applications are chiral: one hand may have the desired therapeutic effect, while the other hand might have no effect, or in the worst case might even be harmful,” said Linke.

In 1986, at Paris-Saclay University, France, discovered a way to tilt chemical reactions towards generating more of one mirror molecule over the other.

Taking this further, in 1995, at the Tokyo University of Science, Japan, started designing chemical reactions to produce only one mirror image. In 2003, he achieved this. His “Soai reaction” gets one form of mirror molecule to amplify itself, in a process known as autocatalysis, so it makes up most of the reaction products.

This has enabled the mass production of drugs, from painkillers to antidepressants and drugs that treat Parkinson’s disease. It has also helped to produce pesticides that improve crop yields.

“This is one of the most exciting days in my life,” said Soai, who phoned in to the press conference.

]]>
2592434
First week of life seems crucial for future allergy and eczema risk /article/2591816-first-week-of-life-seems-critical-for-future-allergy-and-eczema-risk/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Fri, 02 Oct 2026 12:00:00 +0000 /article/2591816-auto-draft/ 2591816 ‘Astonishing’ weight loss when GLP-1 drug used with second medication /article/2591430-astonishing-weight-loss-when-glp1-drug-used-with-second-medication/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Wed, 30 Sep 2026 14:15:00 +0000 /article/2591430-auto-draft/ 2591430